Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients

July 30, 2024

https://www.globenewswire.com/news-release/2024/07/29/2920220/0/en/Grifols-receives-expanded-XEMBIFY-immune-globulin-subcutaneous-human-klhw-label-in-U-S-strengthening-its-Ig-portfolio-for-patients.html

BARCELONA, Spain, July 29, 2024 (GLOBE NEWSWIRE) — Grifols (MCE: GRF, MCE: GRF.P NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that the United States Food and Drug Administration (FDA) has approved an expanded label for XEMBIFY®, the company’s 20% subcutaneous immunoglobulin (SCIg), to include treatment-naïve patients with primary humoral immunodeficiencies (PI).

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.